PureTech Health plc (OTCMKTS:PTCHF – Get Free Report) traded up 0.2% on Tuesday . The company traded as high as $1.74 and last traded at $1.74. 1,100 shares changed hands during trading, a decline of 88% from the average session volume of 9,186 shares. The stock had previously closed at $1.74.
PureTech Health Price Performance
The company has a fifty day simple moving average of $1.87 and a two-hundred day simple moving average of $1.97.
About PureTech Health
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
See Also
- Five stocks we like better than PureTech Health
- 3 Stocks to Consider Buying in October
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- What is a Secondary Public Offering? What Investors Need to Know
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- What is Put Option Volume?
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
